MAPK3 and Hyperglycemia: Activated JNK (activated, e.g., by hyperglycaemia, free fatty acids, cytokines or ER stress [101–105]) and ERK1/2 phosphorylate insulin receptor substrate-1 (IRS-1) and thus prevent signal transduction after insulin binding to the insulin receptor, leading to alterations in insulin action [106].